|
|
Volumn 15 Suppl 1, Issue , 2010, Pages 32-35
|
|
The responsibility to pay for cancer treatments: A health insurer's view of value.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
BEVACIZUMAB;
MONOCLONAL ANTIBODY;
ARTICLE;
BREAST TUMOR;
COST BENEFIT ANALYSIS;
ECONOMICS;
FEMALE;
HEALTH INSURANCE;
HUMAN;
INSURANCE;
LEGAL ASPECT;
NEOPLASM;
ORGANIZATION AND MANAGEMENT;
PERSONNEL MANAGEMENT;
STANDARD;
UNITED STATES;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL;
BREAST NEOPLASMS;
COST-BENEFIT ANALYSIS;
EFFICIENCY, ORGANIZATIONAL;
FEMALE;
HUMANS;
INSURANCE CARRIERS;
INSURANCE, HEALTH;
INSURANCE, LIABILITY;
MINNESOTA;
NEOPLASMS;
PHYSICIAN INCENTIVE PLANS;
|
|
EID: 77953657931
PISSN: None
EISSN: 1549490X
Source Type: Journal
DOI: 10.1634/theoncologist.2010-S1-32 Document Type: Article |
|
Times cited : (4)
|
|
References (0)
|
